Related Experiment Video

Updated: Mar 24, 2026

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

3.1K

[Endoglin (CD105)--a target for visualization and anti-angiogenic therapy for malignant tumors]

I V Smirnov, I V Gryazeva, M P Samoilovich

    Voprosy Onkologii
    |March 22, 2016
    PubMed

    Insights

    Endoglin (CD105) offers a new anti-angiogenic target beyond VEGF, crucial for tumor growth and spread. Targeting CD105 shows promise for novel cancer therapies and diagnostics.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Biochemistry

    Background:

    • Current anti-angiogenic therapies targeting VEGF show limited efficacy.
    • Endoglin (CD105), a TGF-beta superfamily receptor, regulates VEGF-independent angiogenesis.
    • CD105 is highly expressed on tumor endothelial cells and stromal cells, correlating with tumor aggressiveness.

    Purpose of the Study:

    • To explore Endoglin (CD105) as a novel target for anti-angiogenic cancer therapy.
    • To investigate the role of CD105 in tumor angiogenesis and its clinical significance.

    Main Methods:

    • Analysis of CD105 expression in tumor tissues and its correlation with clinical parameters.
    • Detection of soluble endoglin in peripheral blood of cancer patients.
    • Review of monoclonal antibodies targeting CD105 for therapeutic and diagnostic applications.

    Main Results:

    • High CD105 expression in tumor microvessels correlates with increased tumor aggressiveness, lymph node metastasis, and poor prognosis.
    • Soluble endoglin levels in peripheral blood may indicate tumor progression.
    • Monoclonal antibodies against CD105 are potential tools for tumor vessel visualization, direct anti-endothelial effects, and targeted drug delivery.

    Conclusions:

    • Endoglin (CD105) represents a promising therapeutic and diagnostic target for anti-angiogenic cancer therapy.
    • Targeting CD105 may overcome limitations of current VEGF-based anti-angiogenic treatments.
    • CD105-based strategies offer potential for improved cancer treatment outcomes.

    More Related Videos

    Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

    Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

    Published on: November 23, 2014

    10.2K
    Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

    Isolation and Culture Expansion of Tumor-specific Endothelial Cells

    Published on: October 14, 2015

    11.7K

    Related Concept Videos

    Regulation of Angiogenesis and Blood Supply01:24

    Regulation of Angiogenesis and Blood Supply

    Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
    3.9K
    Mechanism of Angiogenesis01:10

    Mechanism of Angiogenesis

    Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
    7.6K